Non-Operating Income/Expense: The sum of all non-operating expenses for the given industry.
Avalyn Pharma Inc. (AVLN) had Non-Operating Income/Expense of $2.35M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-28.93M |
|
-- |
|
-- |
|
$31.29M |
|
$-31.29M |
|
|
Non-Operating Income/Expense |
$2.35M |
$-28.93M |
|
$-28.93M |
|
$-28.93M |
|
$-28.93M |
|
$-28.93M |
|
$-28.93M |
|
$-31.29M |
|
$-31.34M |
|
29.65M |
|
29.65M |
|
$-0.98 |
|
$-0.98 |
|
| Balance Sheet Financials | |
$357.99M |
|
$1.21M |
|
$67.46M |
|
$425.45M |
|
$10.81M |
|
$14.80M |
|
$16.29M |
|
$27.10M |
|
$398.35M |
|
$398.35M |
|
$398.35M |
|
44.33M |
|
| Cash Flow Statement Financials | |
$-55.97M |
|
$-63.69M |
|
$331.54M |
|
$52.31M |
|
$264.20M |
|
$211.88M |
|
$3.98M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
33.12 |
|
-- |
|
-- |
|
0.04 |
|
0.04 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-56.55M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-7.26% |
|
-7.26% |
|
-6.80% |
|
-7.00% |
|
$8.99 |
|
$-1.91 |
|
$-1.89 |
|